Dustin Hess

Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group

A. Naranjo, J. Maris, K. Matthay, 2017, Clinical Cancer Research.

Killer immunoglobulin-like receptor (KIR) and KIR–ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2

Eneida A. Mendonça, Amy K. Erbe, J. Weiss, 2016, Cancer Immunology, Immunotherapy.

Impact of KIR/KIR ligand genotype for neuroblastoma patients in a phase III COG immunotherapy trial.

J. Maris, KyungMann Kim, E. Mendonça, 2016 .